Inactive Instrument

Provention Bio, Inc.

Equities

PRVB

US74374N1028

Pharmaceuticals

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Provention Bio, Inc.(NasdaqGS:PRVB) dropped from S&P Pharmaceuticals Select Industry Index CI
Provention Bio, Inc.(NasdaqGS:PRVB) dropped from S&P Global BMI Index CI
Provention Bio, Inc.(NasdaqGS:PRVB) dropped from S&P TMI Index CI
Improving Confidence in Eurozone Economy Lifts French Shares Amid Q1 Results Outpour MT
Sanofi Completes Provention Bio Acquisition MT
Provention Bio, Inc. Appoints Debora Pellicano as Chief Financial Officer CI
Provention Bio, Inc. Announces Management Changes CI
Sanofi Closes $3 Billion Acquisition of Provention Bio MT
Provention Bio, Inc.(NasdaqGS:PRVB) dropped from NASDAQ Composite Index CI
Sanofi completed the acquisition of 97.1% stake in Provention Bio, Inc.. CI
Sanofi Secures US Antitrust Clearance for $2.9 Billion Provention Bio Takeover MT
Provention Bio, Inc.(NasdaqGS:PRVB) dropped from NASDAQ Biotechnology Index CI
Sanofi wins US drug control from AstraZeneca in Sobi deal AN
Sanofi Extends Offer Period for Provention Bio Takeover Amid US Regulatory Review MT
North American Morning Briefing : Some Calm -2- DJ
HC Wainwright Downgrades Provention Bio to Neutral From Buy, Adjusts Price Target to $25 From $16 MT
North American Morning Briefing : Futures Deep in -3- DJ
SMBC Nikko Downgrades Provention Bio to Neutral From Outperform, Raises Price Target to $25 From $15 MT
Jefferies Downgrades Provention Bio to Hold From Buy, Price Target is $25 MT
Healthcare Shares Climb Amid Deal News -- Healthcare Roundup DJ
Sector Update: Health Care Stocks Close with Solid Monday Gains MT
Sector Update: Health Care Maintaining Monday Rebound MT
Top Midday Gainers MT
Sector Update: Health Care MT
Sector Update: Health Care Stocks Advance in Early Monday Morning Trade MT
Chart Provention Bio, Inc.
More charts
Provention Bio, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing the development and commercialization of investigational therapies that intercept and prevent debilitating and life-threatening immune-mediated diseases. The Company's pipeline includes TZIELD (teplizumab-mzwv), PRV-3279, Ordesekimab and PRV-101. TZIELD (teplizumab-mzwv) is a CD3-directed antibody indicated to delay the onset of stage three T1D in adults and pediatric patients aged eight years and older with stage two T1D. It is also developing TZIELD for use in stage three newly diagnosed T1D patients. PRV-3279 is a humanized bispecific scaffold molecule targeting the B-cell surface proteins for the treatment of SLE and for the prevention of immunogenicity of biotherapeutics. Ordesekimab is a human anti-interleukin 15 (IL-15) monoclonal antibody for the treatment of gluten-free diet non-responsive celiac disease. PRV-101 is a CVB vaccine to prevent acute CVB infections.
More about the company
  1. Stock
  2. Equities
  3. Stock Provention Bio, Inc. - Nasdaq
  4. News Provention Bio, Inc.
  5. Jefferies Adjusts Price Target on Provention Bio to $22 From $18, Maintains Buy Rating